Mount Sinai adopts SOPHiA GENETICS AI platform for cancer genomics

Go back to Mount Sinai adopts SOPHiA GENETICS AI platform for cancer genomics

Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026

April 16, 2026 8:01 AM EDT

SAN DIEGO and NEW YORK, April 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM Platform to advance cancer research and enhance genomic testing capabilities.

... More